On June 27, 2026, Zoetis Inc. was removed from several Russell Top 200 indexes and simultaneously added to the Russell Midcap Index and its value and growth benchmarks. The index reclassification follows an 11% decline in U.S. companion-animal sales and heightened competition, which prompted Zoetis to reset its 2026 revenue guidance to between US$9.68 billion and US$9.96 billion and adjusted EPS to US$6.85 to US$7.00. The company also faces pending securities class actions related to companion-animal disclosures. While the Russell index shift mainly affects which funds hold the stock, the underlying business is pressured by weaker demand for key osteoarthritis treatments like Librela and Solensia.
Zoetis IncWeaker demand for key osteoarthritis treatments Librela and Solensia, with 11% decline in U.S. companion-animal sales.